The effect of dyspepsia and reflux treatment on the number and severity of migraine headache attacks

The effect of dyspepsia and reflux treatment on the number and severity of migraine headache attacks: a clinical trial study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190618043934N28

Enrollment

Registered

2024-08-24

Start date

2024-08-31

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine

Interventions

Intervention 1: Intervention group: Intervention group 1: receiving routine migraine medications including propranolol 20 (manufactured by Hakim Pharmaceutical Company - Iran) every 12 hours and nortr

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Having informed consent to participate in the study Age 18 to 60 years

Exclusion criteria

Exclusion criteria: History of drug use Psychotic disorder Contraindications for drug administration Under treatment for constipation Under the treatment of peptic ulcer Drug sensitivity to drugs related to the treatment of digestive disorders

Design outcomes

Primary

Measure	Time frame
Number of headaches. Timepoint: It is evaluated by a neurology assistant before admission, 2, 4 and 6 months after the intervention and medication. Method of measurement: The neurology assistant asks the patient the number of headaches and records it in the checklist associated with each patient.;Duration of headache. Timepoint: It is evaluated by a neurology assistant before admission, 2, 4 and 6 months after the intervention and medication. Method of measurement: The neurology assistant asks the patient the duration of the headache and records it in the checklist related to each patient.;Severity of headache. Timepoint: It is evaluated by a neurology assistant before admission, 2, 4 and 6 months after the intervention and medication. Method of measurement: The neurology assistant first teaches about the visual and auditory measurement criteria (where 0 is no headache and 10 is the most headache), and then they are asked about the severity of the headache and it is recorded in the checklist related to each patient.	—

Measure

Time frame

Number of headaches. Timepoint: It is evaluated by a neurology assistant before admission, 2, 4 and 6 months after the intervention and medication. Method of measurement: The neurology assistant asks the patient the number of headaches and records it in the checklist associated with each patient.;Duration of headache. Timepoint: It is evaluated by a neurology assistant before admission, 2, 4 and 6 months after the intervention and medication. Method of measurement: The neurology assistant asks the patient the duration of the headache and records it in the checklist related to each patient.;Severity of headache. Timepoint: It is evaluated by a neurology assistant before admission, 2, 4 and 6 months after the intervention and medication. Method of measurement: The neurology assistant first teaches about the visual and auditory measurement criteria (where 0 is no headache and 10 is the most headache), and then they are asked about the severity of the headache and it is recorded in the checklist related to each patient.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Nayer Bodaghi

Birjand University of Medical Sciences

oabstudent@gmail.com+98 56 3238 1500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026